toxicological studies work on formulation, stability, alternative routes of synthesis and chemical analysis will have continued and only when the drug is clearly seen to be worth further investigation will it be given to man in the first human volunteer studies. These are designed to provide information on the blood levels reached, that is the bioavailability from the different formulations, and the pharmacokinetics of the drug in man. At this stage it may not be given to subjects suffering from the disease for which the drug is indicated, even although such subjects volunteer, but it is followed extensively at different dose levels in normal man until sufficient information is obtained. Finally, all the data obtained is submitted to the Committee on Safety of Medicines and the Clinical Trial Certificate requested; at this time the supplies for the first clinical trials are made and bottled.
Depending on the drug, the time from the first synthesis or isolation to the granting of the Certificate may be anything from six to ten years, and it has been estimated that for every (Bull 1959 Based on this thinking, Maxwell (1969) has defined a clinical trial as a 'scientific experiment in which a therapy or therapeutic procedure is studied in patients'. Thus in anesthetics, a clinical trial could embrace study of a new technique, modification of an existing technique, a number of interrelated drugs or, in its simplest and most common form, be limited to one drug. We are here discussing drug trials.
Aims ofTrials While one thinks of a clinical trial primarily as a study of a new drug, the aims are wider than this:
(1) Assessment of the activity of a new product which has a unique action or an action which is present to a unique degree. (2) Before undertaking a clinical trial the investigator will have essential data from animal experiments and from pharmacological studies carried out on volunteers and have satisfied himself with the findings. Nevertheless, the initial results may point to the need for further data from these sources and to continue without this would be unethical. Thus embarking on a trial does not commit one to finishing it if untoward side-effects are found.
Fig 1 suggests two types of clinical trialscontrolled and group. The latter may be multicentred and ideally it is organized by the person responsible for the initial study. This is not the same as 'limited release' or 'monitored release'. The initial controlled trial is designed to reduce variables to the minimum and in anesthesia it is often carried out only on fit patients. It may give results which are of little importance in everyday clinical practice: the observers are trained to detect small variations which are of no real clinical significance, the monitoring may be very sophisticated and, in subjective studies, the continuous presence of the physician can have a 'placebo' (pleasing) effect. In contrast, a 'group' trial with less rigorous patient-selection and the opinion of a large number of clinically-orientated observers is very helpful indeed and in anesthetic practice plays an important part in drug evaluation prior to general release. It should always be remembered that controlled clinical trials give results which, strictly speaking, are only applicable to the situation under which they were obtained. The importance of this varies with the type of drug. Thus, in aneesthesia, findings with relaxants and general anesthetics apply under any conditions, but those with antiemetics or tranquillizers apply only to the study situation.
Interactions with non-anesthetic drugs will not be normally detected in a properly controlled clinical trial, since such variables will be eliminated in its design. Design A clinical trial, like other scientific experiment, requires logical pre-thinking and a clear statement of intent. The plan and instructions which guide the study from the protocol which must be tailormade for each clinical trial.
The details which must be written down will vary with the experience and capability of the participants but should be such that another person could carry out at least part of the trial if the original worker is not available. The plan may have to be modified, even more than once, in the light of experience with the first few cases, but thereafter it should be strictly adhered to (Fig 2) . Criticism of the protocol by one's colleagues is a valuable exercise before embarking on the main part of the study and statisticians must be satisfied with the plan. Maxwell (1969) advises that the final protocol should be a near perfect compromise between theoretical desires and practical necessities. Other useful advice from the same author is that the introduction to the scientific paper which will report the findings should be written before the study starts. This should include the justification of the trial, lest in time this be forgotten. The aim of the protocol and that of the subsequent publication are synonymous and the form can be used as a basis of the methodology section of the paper. It should include design, population, documentation, dosage dispensing, randomization, assessments, statistics, dropouts and significance levels. While one may be tempted to modify an existing protocol for use with a new drug, this rarely works, particularly in anmthesia.
Most new agents will have solubility ccefficients, time constants and dose-response effects which differ from existing agents to which the worker is accustomed.
Control or Standardization
It is often assumed that statistical analysis of results guarantees their validity, but this can only be achieved if the design of the trial allows for adequate standardization. One is inclined to think of control as applying to patients, for, as Sir Austin Bradford Hill (1955) has pointed out, 'in its most rigorous form' the clinical trial 'demands equivalent groups of patients concurrently treated in different ways'.
However, there are drug factors which have to be standardized. These include stability, interactions, route of administration, dosage (equivalents) and comparability. In addition, one has to ensure that the drug scheduled for study is in fact the one studied. Dosage can affect the incidence and severity of side-effects of barbiturates, relaxants and narcotic analgesics, and ideally clinical trials of these drugs should initially be carried out at several dose levels. It is difficult to define precisely what is meant by the term equipotent and clinical estimates often take duration of action into consideration. Observer bias is naturally most important in studies of subjective effects and it can be minimized by randomization of treatment, employing the blind (or double blind) technique and by the use of a standard preparation. Although the concurrent study of several drugs reduces bias it may prolong the trial to the extent of inducing observer boredom or presenting a challenge to 'break the key'.
Methods of drug assessment will vary, depending on whether one is dealing with subjective or objective effects. Each involves recording of the observation, documentation, statistical analysis and an assessment as to whether the finding is of clinical importance. Categorization of subjective effects is a particularly useful method for drug study, but necessitates a similar assessment of the effect of a placebo and standard preparation.
Placebos play an important part in the study of subjective responses. A placebo is something which pleases the patient; it is a therapy which is not a therapy, but an imitation of a therapy. Its use is discussed in several papers to which readers are referred (Benson et al. 1966 , Parkhouse 1964 , Wilson 1962 .
The design of the trial cannot be discussed here but, in general, anaesthetists are concerned with 'comparison' studies involving a new and a standard therapy. This can involve predetermined numbers of patients or a sequential design may be employed. In general, trials will be of the 'before and after' type, comparing the condition of the patient before and after receiving the drugs under study. Cross-over trials are generally not applicable to anesthesia.
Clinical trials in anmesthesia differ in many ways from clinical trials in other branches of medicine. Often they cannot be carried out double blind and they may involve multiple doses of drugs. A direct criterion, i.e. measurement of action of the drug, may not be the best method of overall assessment, and a multifacet study may necessitate the use of a scoring scheme. This can be based on a combination of objective and subjective data. Finally the use of a placebo may be inappropriate in anesthetic clinical trials.
Only a few of the important practical aspects of clinical trials have been discussed here, and for details readers are referred to papers by Atkins (1966) , Dundee (1971) , Hamilton (1967) and Hill (1967) , as well as to the Symposium organized by the Medical Advisers to the Pharmaceutic Industry (Harris & Fitzgerald 1970) .
